Evaluating Blue Zones Demography in Response to Recent Critiques
January 6, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Clenpiq, Prepopik
Synonyms :
sodium picosulfate, citric acid, and magnesium oxide
Class :
Laxative
Brand Name :
Clenpiq, Prepopik
Synonyms :
sodium picosulfate, citric acid, and magnesium oxide
Class :
Laxative
Split-dose regimen:
Dose 1: 150 ml (5 oz) orally once in the evening before the colonoscopy between 5-9 PM
Dose 2:150 ml (5 oz) orally 5 hours before the colonoscopy.
Day-before regimen:
Dose 1: 150 ml (5 oz) orally early evening before the colonoscopy between 4-6 PM
Dose 2: 150 ml (5 oz) orally 6 hours after 10 PM-12 AM before the colonoscopy.
Split-dose regimen:
Dose 1: 1packet orally once in the evening before the colonoscopy between 5-9 PM
Dose 2: 1 packet orally 5 hours before the colonoscopy.
Day-before regimen:
Dose 1: 1 packet orally early evening before the colonoscopy between 4-6 PM
Dose 2: 1 packet orally 6 hours after 10 PM-12 AM before the colonoscopy.
amoxicillin and clavulanate potassium
it may reduce the therapeutic effect of sodium picosulfate
lansoprazole, amoxicillin, and clarithromycin
it may reduce the therapeutic effect of sodium picosulfate
bismuth subcitrate, metronidazole and tetracycline
it may reduce the therapeutic effect of sodium picosulfate
it may reduce the therapeutic effect of sodium picosulfate
it may reduce the therapeutic effect of sodium picosulfate
lansoprazole, amoxicillin, and clarithromycin
may decrease the therapeutic effect when combined with sodium picosulfate
may decrease the therapeutic effect when combined with sodium picosulfate
may decrease the therapeutic effect when combined with sodium picosulfate
may decrease the therapeutic effect when combined with sodium picosulfate
may decrease the therapeutic effect when combined with sodium picosulfate
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
it may increase the risk of adverse effects of sodium sulfate
may decrease the therapeutic effect of antibiotics
may decrease the therapeutic effect of antibiotics
may decrease the therapeutic effect of antibiotics
may decrease the therapeutic effect of antibiotics
neomycin/polymyxin B/gramicidin ophthalmic
may decrease the therapeutic effect of Antibiotics
polyethylene glycol and electrolytes
May enhance the adverse/toxic effect of polyethylene Glycol-electrolyte Solution.
may enhance the pharmacodynamic synergistic effect when combined
it may increase the risk of adverse effects of sodium sulfate
may decrease the therapeutic effect of Antibiotics
it may increase the risk of adverse effects of Sodium Polystyrene Sulfonate
it may increase the risk of adverse effects of Sodium Polystyrene Sulfonate
it may increase the risk of adverse effects of Sodium Polystyrene Sulfonate
sodium picosulfate, citric acid, and magnesium oxide
it may increase the risk of adverse effects of Sodium Polystyrene Sulfonate
it may increase the risk of adverse effects of Sodium Polystyrene Sulfonate
It may enhance the risk of adverse reactions when combined with Laxatives
It may enhance the risk of adverse effects when combined with Prolactine inhibitors
sodium picosulfate citric acid and magnesium oxide
it may increase the risk of adverse effects of Sodium Polystyrene Sulfonate
Laxatives may increase the hypokalemic effect of dichlorphenamide
It may increase the hypokalemic effect when combined with laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
bismuth subcitrate, metronidazole and tetracycline
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
bladderwrack may raise the laxative efficacy
Adverse drug reactions:
Frequency Defined
>10%:
Altered blood pressure
change in pulse
Hypermagnesemia
Decreased estimated GFR
1-10%:
Headache
dizziness
Decreased serum potassium
hypochloremia
decreased serum sodium
decreased serum calcium
Dehydration
decreased serum bicarbonate
Nausea
Vomiting
abdominal pain
Increased serum creatinine
Pregnancy warnings:
US FDA pregnancy category: Not assigned.
Breastfeeding warnings:
The release of the drug into the human breastmilk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: sodium picosulfate, citric acid, and magnesium oxide
Pronounced: SOE-dee-um-PEE-koe-SUL-fate, SIT-rik-AS-id, and mag-NEE-zee-um-OX-ide,
Why do we use sodium picosulfate, citric acid, and magnesium oxide?
Sodium picosulfate, citric acid, and magnesium oxide is a laxative drug which is used in combination to cause diarrhea for emptying the colon before colonoscopy.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
